Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
RNAP(Bacterial DNA-directed RNA polymerase) | 1 |
DHODH(Dihydroorotate dehydrogenase) | 1 |
Target |
Mechanism DHODH inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Sep 2012 |
Target |
Mechanism RNAP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date21 May 1971 |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Teriflunomide ( DHODH ) | Radiologically isolated syndrome More | Phase 3 |
Rifampin ( RNAP ) | Prosthetic joint infection More | Phase 3 |
B-subunit of non-toxic cholera toxin vaccine(Centre Hospitalier Universitaire de Nice) | Infectious Diseases More | Pending |